

# Pneumococcal Vaccination Recommendations for Children<sup>1</sup> and Adults by Age and/or Risk Factor

## Routine Recommendations

for Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)

<b>For children age 2 months and older</b>	Administer PCV13 series to all children beginning at age 2 months, followed by doses at 4 months, 6 months, and 12–15 months (booster dose).	<b>For adults age 65 years and older</b>	Administer 1 dose of PPSV23 at age 65 years. PCV13 may be given after making a shared clinical decision between the patient and the healthcare provider. <sup>2</sup>
--	--	--	---

## Risk-based Recommendations

People with Underlying Medical Conditions or Other Risk Factors

Risk Group	Underlying medical condition or other risk factor	PCV13			PPSV23	
		Administer PCV13 doses needed to complete series to children through age 71 months	Administer 1 dose to PCV13-naïve children age 6 through 18 years	Administer 1 dose to PCV13-naïve adults age 19 years and older	Administer 1 dose of PPSV23 at age 2 through 64 years	Administer a second dose of PPSV23 5 years after first dose if age younger than 65 years
Immuno-competent	Chronic heart disease <sup>3</sup>	X			X	
	Chronic lung disease <sup>4</sup>	X			X	
	Diabetes mellitus	X			X	
	Cerebrospinal fluid leak	X	X	X	X	
	Cochlear implant	X	X	X	X	
	Alcoholism				X	
	Chronic liver disease, cirrhosis				X	
Functional or anatomic asplenia	Sickle cell disease/other hemoglobinopathy	X	X	X	X	X
	Congenital or acquired asplenia	X	X	X	X	X
Immuno-compromised	Congenital or acquired immunodeficiency <sup>5</sup>	X	X	X	X	X
	HIV	X	X	X	X	X
	Chronic renal failure	X	X	X	X	X
	Nephrotic syndrome	X	X	X	X	X
	Leukemia	X	X	X	X	X
	Lymphoma	X	X	X	X	X
	Hodgkin disease	X	X	X	X	X
	Generalized malignancy	X	X	X	X	X
	Iatrogenic immunosuppression <sup>6</sup>	X	X	X	X	X
	Solid organ transplant	X	X	X	X	X
Multiple myeloma	X	X	X	X	X	

<sup>1</sup> For PCV13 vaccination of healthy children, see “Recommendations for Pneumococcal Vaccine Use in Children” at [www.immunize.org/catg.d/p2016.pdf](http://www.immunize.org/catg.d/p2016.pdf).

<sup>2</sup> PCV13 is no longer routinely recommended for adults age 65 years and older. Considerations include living or traveling in areas with low PCV13 vaccination of children, living in a long-term care facility, having a chronic medical condition, smoking, or alcoholism.

<sup>3</sup> Particularly cyanotic congenital heart disease and cardiac failure in children; including congestive heart failure and cardiomyopathy in all ages; excluding hypertension in adults.

<sup>4</sup> Including asthma in children if treated with high-dose oral corticosteroid therapy, as well as chronic obstructive pulmonary disease (COPD), emphysema, and asthma in adults.

<sup>5</sup> Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).

<sup>6</sup> Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.